Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

34
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
34
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.6K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.4K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.2K
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Leukemia research·2014
Same author

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.

Autophagy·2014
Same author

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Nature medicine·2014
Same author

Entosis, a key player in cancer cell competition.

Cell research·2014
Same author

Cytokines reinstate NK cell-mediated cancer immunosurveillance.

The Journal of clinical investigation·2014
Same author

Cell biology. Metabolic control of cell death.

Science (New York, N.Y.)·2014
Same journal

A guide to CAR T cell therapies: development, current status and future prospects.

Nature reviews. Immunology·2026
Same journal

Macrophages in embryonic development.

Nature reviews. Immunology·2026
Same journal

Glycolytic capacity instructs tumour vasculature and response to immunotherapy.

Nature reviews. Immunology·2026
Same journal

Vaginal NK cells limit epithelial barrier disruption during infection.

Nature reviews. Immunology·2026
Same journal

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same journal

T cell engagers in autoimmune diseases.

Nature reviews. Immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K

Type I interferons in anticancer immunity.

Laurence Zitvogel1, Lorenzo Galluzzi2, Oliver Kepp3

  • 11] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].

Nature Reviews. Immunology
|June 2, 2015
PubMed
Summary
This summary is machine-generated.

Type I interferons (IFNs) are crucial for antiviral immunity and cancer immunosurveillance. Their presence enhances cancer treatments and correlates with better patient outcomes, driving new immunotherapy development.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

2.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

2.0K

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Type I interferons (IFNs) are critical for antiviral immune responses.
  • Emerging evidence highlights their role in cancer immunosurveillance.
  • IFNs are produced by malignant cells and tumor-infiltrating dendritic cells.

Purpose of the Study:

  • To review the role of type I IFNs in cancer immunosurveillance.
  • To discuss the impact of type I IFNs on cancer therapies.
  • To explore the development of type I IFN-based cancer immunotherapies.

Main Methods:

  • Literature review of existing research on type I IFNs in cancer.
  • Analysis of clinical data correlating IFN levels with patient outcomes.
  • Overview of current and emerging type I IFN-based cancer treatments.

Main Results:

  • Type I IFNs regulate autocrine and paracrine circuits in cancer immunosurveillance.
  • The efficacy of many conventional and novel cancer therapies depends on intact type I IFN signaling.
  • Intratumoral type I IFN expression correlates with favorable patient prognosis in several cancer types.

Conclusions:

  • Type I IFNs are pivotal in both innate antiviral immunity and adaptive anti-tumor responses.
  • Targeting type I IFN pathways represents a promising strategy for enhancing cancer immunotherapy.
  • Further research into type I IFN-based therapies could significantly improve cancer treatment outcomes.